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Abstract
Background: The objective of this trial was to compare the blood-pressure lowering efficacy of amlodipine/
losartan combination with amlodipine monotherapy after 6 weeks of treatment in Korean patients with stage 2
hypertension.
Results: In this multi-center, double-blind, randomized study, adult patients (n = 148) with stage 2 hypertension
were randomized to amlodipine 5 mg/losartan 50 mg or amlodipine 5 mg. After 2 weeks, patients with systolic
blood pressure (SBP) > 140 mmHg were titrated to amlodipine 10 mg/losartan 50 mg or amlodipine 10 mg. After
4 weeks of titration, hydrochlorothiazide 12.5 mg could be optionally added to both groups. The change from
baseline in SBP was assessed after 6 weeks. The responder rate (defined as achieving SBP < 140 mmHg or DBP <
90 mmHg) was also assessed at 2, 6 and 8 weeks as secondary endpoints. Safety and tolerability were assessed
through adverse event monitoring and laboratory testing. Baseline demographics and clinical characteristics were
generally similar between treatment groups. Least-square mean reduction in SBP at 6 weeks (primary endpoint)
was significantly greater in the combination group (36.5 mmHg vs. 31.6 mmHg; p = 0.0117). The responder rate in
SBP (secondary endpoints) was significantly higher in the combination group at 2 weeks (52.1% vs. 33.3%; p =
0.0213) but not at 6 weeks (p = 0.0550) or 8 weeks (p = 0.0592). There was no significant difference between
groups in the incidence of adverse events.
Conclusion: These results demonstrate that combination amlodipine/losartan therapy provides an effective and
generally well-tolerated first line therapy for reducing blood pressure in stage 2 hypertensive patients.
Trial Registration: ClinicalTrials.gov: NCT01127217
Keywords: hypertension, amlodipine, losartan
Background
Hypertension has been recognized as an important risk
factor for cardiovascular disease and is a leading risk fac-
tor for mortality [1]. Each year, the diagnosis and treat-
ment of hypertension is increasing. By the year 2025, the
prevalence is predicted to increase by 60% to approxi-
mately 1.56 billion worldwide, highlighting the need for
improvement in the management and prevention of
hypertension [2]. Inadequate recognition of hypertension,
poor compliance of patients taking multiple drugs, and
the reluctance of physicians to intensify antihypertensive
therapy may account for the increasing burden of disease
[3-5]. One way to overcome these barriers is through
development of various fixed dose combination agents to
treat hypertension.
Current US and European guidelines for the treatment
of stage 2 hypertension recommend early initiation of
combination treatment consisting of two anti-hypertensive
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any medium, provided the original work is properly cited.drugs from different therapeutic classes since most hyper-
tensive patients require two or more anti-hypertensive
drugs to achieve their target blood pressure level [3,6].
Combination treatment for hypertension as initial therapy
may simplify treatment and improve drug compliance by
reducing the burden of taking multiple drugs [3,6]. In
addition to increasing compliance, combination therapy
may have other advantages over monotherapy, such as
synergistic mechanisms of action for controlling hyperten-
sion and reduced side effects. For example, the capillary
edema resulting from preferential arteriolar vasodilatation
by dihydropyridine calcium channel blockers (CCB) can
be ameliorated by angiotensin-receptor blockers (ARBs) or
angiotensin converting enzyme (ACE) inhibitors; and the
stimulation of the rennin-angiotensin system (RAS)
induced by CCBs with potent vasodilatory and intrinsic
natriuretic effects may be blocked by ARB and ACE inhi-
bitors, increasing the blood pressure lowering effect [7].
The fixed dose combination of losartan and amlodipine is
among the newer antihypertensive combinations that have
been extensively studied and shown to be effective in the
management of hypertension [8,9]. The objective of this
trial was to compare the blood pressure lowering efficacy
and tolerability profile of the combination of amlodipine/
losartan with amlodipine monotherapy after 6 weeks of
treatment in patients with stage 2 hypertension.
Methods
Study population
This was an 8-week, double blind, randomized study con-
ducted at 8 hospitals in Korea. The study protocol was
approved by the Korean FDA and the local ethical review
boards of each hospital (Konkuk University Medical Cen-
ter, Hallym University Kangnam Sacred Heart Hospital,
Kangbuk Samsung Hospital, KyungHee University Medi-
cal Center, Korea University Anam Hospital, Seoul
National University Hospital, Asan Medical Center, and
Chonnam National University Hospital). The study was
conducted in accordance with the ethical principles of the
current Declaration of Helsinki. Subjects signed informed
consent prior to any relevant laboratory tests.
Adults aged 18 or older with stage 2 hypertension [diag-
nosed according to the criteria set forth in the 7
th Report
of the Joint National Committee on Prevention, Detection,
evaluation, and Treatment of High Blood Pressure (JNC 7)
[3] were eligible for the study. Subjects on anti-hyperten-
sive drugs were eligible if their sitting systolic blood pres-
sure (SBP) was ≤180 mmHg and sitting diastolic blood
pressure (DBP) was ≤110 mmHg. These subjects under-
went a 3- to 7-day washout period prior to randomization.
Subjects were randomized if they had SBP ≥ 160 mmHg
and ≤199 mmHg and DBP ≥ 80 mmHg and ≤119 mmHg
at randomization.
Subjects were excluded if they had variability of ≥ 20
mmHg in SBP or ≥ 10 mmHg in DBP in three measure-
ments at screening. Subjects who had been treated with
systemic steroid hormones, anesthetics, tri- & tetra-cyclic
antidepressants, nonsteroid anti-inflammatory drugs,
and/or oral contraceptives for 3 months, or had renal or
hepatic disease, and women that were pregnant or nur-
sing were also excluded from the study.
Subjects were randomized into two treatment groups:
amlodipine 5 mg/losartan 50 mg or amlodipine 5 mg
using an allocation ratio of 1:1. Subjects were instructed to
take their corresponding investigational products with
matching placebos for two weeks starting at randomiza-
tion. Information on blinding was provided to the princi-
pal investigators in sealed forms. Sealed status was
maintained until Korean FDA inspection. Unblinding was
only considered in the event of a significant medical
emergency.
All subjects had their blood pressure measured at each
visit using mercury sphygmomanometers provided by the
sponsor and the same investigator measured blood pres-
sure at each visit, if possible. At screening, blood pressure
was measured 3 times in both arms and the arm with
higher mean SBP was selected as the reference arm. At the
remaining visits, blood pressure was measured from the
reference arm 3 times and the mean value was used. Caf-
feine, exercise and smoking were not allowed at least 30
minutes prior to blood pressure measurements.
At Week 2, subjects taking amlodipine 5 mg/losartan
50 mg with measured SBP ≥ 140 mmHg were prescribed
the increased dose of amlodipine 10 mg/losartan 50 mg,
while subjects taking amlodipine 5 mg with measured
SBP ≥ 140 mmHg were prescribed the increased dose of
amlodipine 10 mg for six weeks. Subjects with measured
SBP < 140 mmHg maintained their existing dose of
amlodipine for the remaining six weeks. At six weeks, the
investigators could add hydrochlorothiazide (HCTZ)
12.5 mg to the treatment regimen if the measured SBP
was ≥ 140 mmHg.
Compliance was checked and recorded at each visit
following randomization. Actual doses were recorded by
counting the number of tablets. If compliance was <
80% the subject was excluded from the Per Protocol
(PP) population.
Efficacy Assessment
The primary endpoint was the change from baseline in
SBP after 6 weeks of treatment. Secondary endpoints were
the change from baseline in SBP after 2 and 8 weeks of
treatment, the change from baseline in DBP after 2, 6, and
8 weeks of treatment, and the responder rates, defined as
the percentage of patients who achieved target blood pres-
sure (SBP < 140 mmHg or DBP < 90 mmHg) or achieved
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20 mmHg and 10 mmHg, respectively.
Safety Assessment
A safety evaluation was performed on all patients who
were randomized and took at least one dose of study
drug. Adverse events were assessed; and laboratory tests,
including hematology, blood chemistry, and urine analy-
sis, as well as physical examination, pulse and electrocar-
diogram were conducted.
Statistical analysis
A sample size of 136 subjects was required for at least 85%
power and a significance level of 0.05 to detect the differ-
ence in change from baseline between treatment groups.
A standard deviation of 13.6 mmHg and a between group
difference of 7.0 mmHg was assumed based on a previous
phase II study (unpublished data). It was estimated that
approximately 160 subjects (80 subjects in each treatment
group) should be screened in order to reach 72 rando-
mized subjects in each treatment group.
The primary population for analysis was the intent-to-
treat (ITT) population, defined as all randomized patients
who had a baseline blood pressure measurement and at
least 1 post baseline efficacy measurement. Efficacy data
were also analyzed using the PP population to ensure
consistency. For continuous demographic variables,
mean, SD, minimum and maximum values were deter-
mined and compared by T-test or Wilcoxon rank sum
test. For categorical demographic variables, absolute and
relative frequencies were determined and compared by
c
2-test or Fisher’s exact test. The primary efficacy vari-
able (change in SBP from baseline to week 6) was ana-
lyzed using analysis of covariance (ANCOVA). The
absolute and relative frequencies of SBP < 140 mmHg,
DBP < 90 mmHg, SBP reduction > 20 mmHg, DBP
reduction > 10 mmHg, and responder rate in terms of
changes after 4 and 6 weeks of treatment relative to base-
line were determined and compared by using c
2-test or
Fisher’s exact test. No adjustments were made for
multiplicity.
Results
Patient Disposition and Baseline Characteristics
The flow of subjects through the study is shown in
Figure 1. A total of 187 subjects were screened and 149
were randomized. One subject in the amlodipine/losar-
tan combination group did not take study drug; there-
fore, 73 subjects were included in the amlodipine/
losartan combination group and 75 were included in the
amlodipine monotherapy group for the safety analysis
and the ITT population. The PP population consisted of
131 subjects: 64 in the amlodipine/losartan combination
group and 67 in the amlodipine monotherapy group
(Figure 1). Fourteen subjects discontinued prior to com-
pleting the study. Sixty five subjects (87.8%) in the amlo-
dipine/losartan group and 70 subjects (93.3%) in the
amlodipine group completed the trial (p = 0.2503).
Demographics and baseline characteristics were similar
between treatment groups except for the rates of concur-
rent alcohol drinking, which were significantly different
between treatment groups (67.1%, 49/73 in the amlodi-
pine/losartan combination group, and 84.0%, 63/75 in the
amlodipine monotherapy group; p = 0.0499; Table 1). The
mean SBP/DBP was 169.0/103.4 mmHg in the amlodi-
pine/losartan combination group and 170.5/102.3 mmHg
in the amlodipine monotherapy group.
Efficacy
The least-square mean change from baseline in SBP after
6 weeks was significantly greater in the amlodipine/losar-
tan combination group (36.5 mmHg) compared with the
amlodipine monotherapy group [(31.6 mmHg) difference
= -4.94 mmHg (95% confidence interval: -8.76, -1.11 p =
0.0117)] (Figure 2). The results of the PP population analy-
sis were consistent with the analysis of the ITT population.
There was a significantly greater reduction from baseline
in SBP in the amlodipine/losartan combination group
compared with the amlodipine monotherapy group at
Week 8 (p = 0.0199), and although the reduction was
numerically greater in the amlodipine/losartan combina-
tion group compared with the amlodipine monotherapy
group at week 2, the difference was not statistically signifi-
cant (p = 0.0790; Figure 2). Although the difference in
DBP reduction between the two groups increased continu-
ously by treatment period until Week 8, there was no sig-
nificant difference between groups at any time point
(Figure 3).
At Week 2, 38/73 subjects (52.1%) in the amlodipine/
losartan combination group compared with 25/75 sub-
jects (33.3%) in the amlodipine monotherapy group
achieved the target SBP < 140 mmHg, and this differ-
ence was significantly different (p = 0.0213; Figure 4).
At Weeks 6 and 8, 58/73 subjects (79.5%) and 57/73
subjects (78.1%), respectively, in the amlodipine/losartan
combination group compared with 49/75 subjects
(65.3%) and 48/75 subjects (64.0%), respectively, in the
amlodipine monotherapy group achieved the target SBP
< 140 mmHg, and these differences were not signifi-
cantly different (p = 0.0550 and p = 0.0592; Figure 4).
Changes were similar between the two groups in the
cumulative responder rate for target DBP level < 90
mmHg, SBP reduction > 20 mmHg, and DBP reduction
> 10 mmHg at Week 2 (90.4% in the amlodipine/losar-
tan combination group vs 85.3% in the amlodipine
monotherapy group, p = 0.3447), at Week 6 (89.0% in
the amlodipine/losartan combination group vs 90.7% in
the amlodipine monotherapy group, p = 0.7432,) and at
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group vs 92.0% in the amlodipine monotherapy group, p
= 0.2758; Figure 5). At Weeks 2 and 6, the analysis
results for the PP population were similar to those of
the ITT population. However, at Week 8 in the PP
population, the responder rate was significantly higher
in the amlodipine/losartan combination group vs. the
amlodipine monotherapy group (100.0% vs. 91.0%; p =
0.0280).
In ITT analysis group, the rate of subjects with dose
escalation after 2 weeks of treatment in the amlodipine/
losartan combination group (47.2%, 34/72) was lower
than that of the amlodipine monotherapy group (64.8%,
46/71). The rate of subjects with treatment of HCTZ
12.5 mg after 6 weeks of treatment in the amlodipine/
losartan combination group (16.7%, 11/66) was also
lower than that of the amlodipine monotherapy group
(31.4%, 22/70).
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(n = 187) 
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(n = 149) 
Excluded 
(n = 38) 
 
 
 
 
 
 
 
 
 
Discontinued (n=5) 
Withdrew consent: 1 
Inclusion/exclusion: 1 
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Other: 2 
Protocol  Deviation  (n=3) 
Completers 
(n=  70)    
PP population 
  (n = 67) 
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(n=7 5 )
Amlodipine 
(n = 75) 
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ITT population   
(n = 73) 
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(n = 64) 
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Adverse event: 2 
Other: 3 
Completers 
(n=  65)    
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Discontinued - Other 
Amlodipine/Losartan 
(n = 74) 
Figure 1 Patients Disposition (ITT: intention to treatment, PP: Per protocol).
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A total of 86 treatment emergent adverse events (TEAE)
were reported in 47 subjects [44 in 23 subjects (31.5%)
in the amlodipine/losartan combination group and 42 in
24 subjects (32.0%) in the amlodipine monotherapy
g r o u p ;T a b l e2 ] .T h e r ew a sn os i g n i f i c a n td i f f e r e n c ei n
the incidence of reported adverse events between
Table 1 Demographics and Baseline Characteristics in the ITT population (ITT = 148 subjects)
Amlodipine/Losartan Amlodipine p-value
(N = 73) (N = 75)
Age (year) 0.6654
(a)
Mean 54.9 55.6
SD 11.0 9.7
range(min~max) 46.0
(31.0~ 77.0)
45.0
(33.0~ 78.0)
Gender 0.2964
(b)
Male 52 (71.2) 59 (78.7)
Female 21 (28.8) 16 (21.3)
Height (cm) 0.7504
(a)
Mean 166.2 165.8
SD 7.9 6.9
Body Weight (kg) 0.7702
(a)
Mean 71.2 70.7
SD 12.4 10.0
Alcohol 0.0499
(b)*
non alcohol drinker 19 (26.0) 10 (13.3)
Historical alcohol drinker 5 (6.9) 2 (2.7)
Alcohol drinker 49 (67.1) 63 (84.0)
Smoking 0.3436
(b)
Non smoker 37 (50.7) 32 (42.7)
Historical smoker 14 (19.2) 22 (29.3)
Smoker 22 (30.1) 21 (28.0)
SBP (mmHg) 0.3466
(a)
Mean 169.0 170.5
SD 9.2 9.8
DBP (mmHg) 0.4099
(a)
Mean 103.4 102.3
SD 8.68 8.0
(a) Unpaired T-test
(b) Pearson’s chi-square test
*Statistically significant difference
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Figure 2 Change from baseline in SBP (mmHg) in the ITT
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There were 3 subjects (4.1%) in the amlodipine/losartan
group and 2 subjects (2.7%) in the amlodipine group
that reported TEAEs considered moderate in intensity.
There was one TEAE (1.3%) reported in the amlodipine
monotherapy group that was considered severe. Thirty
four adverse events considered related to study drug
were reported: 14 in 8 subjects (11.0%) from the amlodi-
pine/losartan group and 20 in 13 subjects (17.3%) from
the amlodipine monotherapy group. The most fre-
quently reported treatment related adverse events
included dizziness, headache, somnolence, hot flush, and
peripheral edema. Two subjects (2.7%) in the amlodi-
pine/losartan combination group and 1 subject (1.3%) in
the amlodipine monotherapy group reported serious
adverse events. No deaths were reported during this
trial (Table 2).
Discussion
The results of this study demonstrated that the amlodi-
pine/losartan 5/50 mg combination was significantly
more effective at reducing SBP than amlodipine
monotherapy after 6 weeks of therapy in stage 2 hyper-
tensive patients. Responder rates for SBP < 140 mmHg
were significantly greater at Week 2 in the combination
group, suggesting a more rapid onset of action, and
were numerically greater in the combination group at
Weeks 6 and 8, with p-values nearing statistical signifi-
cance. Both treatments were generally well tolerated.
These results support the recommendations of the JNC-
7, the European Society of Hypertension, and the Tai-
wan Society of Cardiology Guidelines for the Manage-
ment of Hypertension, which advocate early initiation of
combination treatment consisting of two anti-hyperten-
sive drugs with complimentary mechanisms of action
for stage 2 hypertension patients [3,6,10]
Losartan and amlodipine are frequently used as first-line
therapy in hypertensive patients, [9,11,12] and combining
these two drugs has also been shown to be effective in
lowering blood pressure [13,14]. The results of this study,
in which a fixed dose combination was utilized, support
those earlier studies and extend their findings to demon-
strate significant reductions in blood pressure in patients
with stage 2 hypertension. Of note, the rate of dose escala-
tion, as well as the addition of HCTZ, was lower in the
amlodipine/losartan combination group compared with
the amlodipine monotherapy group after 2 weeks of treat-
ment. This is consistent with the results of the responder
rates which showed greater achievement of SBP < 140
mmHg with the combination treatment vs. monotherapy
at Week 2 and supports the use of the combination regi-
men as a first-line therapy in patients with stage 2 hyper-
tension. Not only was the improvement in SBP greater
with the combination, the number of drugs required to
achieve target was limited to 1 (rather than 2 or more) for
the majority of patients on combination throughout the
trial. Therefore, these results provide support for the fixed
dose combination of amlodipine/losartan 10/50 as an
effective and generally well-tolerated first-line option for
patients with stage 2 hypertension through the potential
improvement of compliance and rapid onset of action.
Several different combination therapies have been
shown to effectively treat hypertension. In two separate
studies, the combination CCB-ACE inhibitor benazepril/
amlodipine was shown to be significantly more effective in
reducing blood pressure, and more patients achieved
blood pressure control compared with amlodipine mono-
therapy [15,16]. Similar results were observed in a study of
the CCB-ACE inhibitor combination enalapril/felodipine
[17]. In the ACCOMPLISH trial, it was reported that the
CCB-RAS inhibitor combination benazepril/amlodipine
was superior to the CCB-diuretic combination benazepril-
hydrochlorothiazide in reducing cardiovascular events in
patients with hypertension who were at high risk for such
events [18]. However, ACE inhibitors affect kinin metabo-
lism and are associated with a high incidence of dry
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Figure 4 Responder rate for SBP < 140 mmHg at Week 2,
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combined with amlodipine to reduce blood pressure.
Several studies combining amlodipine with an ARB have
demonstrated superior efficacy over monotherapy and
comparable tolerability in patients of different races/ethnic
origin. The EX-STAND trial showed that the combination
therapy of amlodipine and valsartan (5/160 mg to 10/320
mg) achieved greater reductions in blood pressure after 8
weeks of treatment and faster onset of action in black sub-
jects with stage 2 hypertension compared with corre-
sponding component amlodipine monotherapies (33.3
mmHg vs. 26.6 mmHg, p < 0.001) [19]. In Indian subjects
with stage 2 hypertension, the combination of telmisartan/
amlodipine 40/5 mg was shown to be significantly more
effective after 12 weeks of treatment (p < 0.05), and more
patients achieved blood pressure control compared with
amlodipine monotherapy (p < 0.05) [20]. The COACH
study showed that combination olmesartan and amlodi-
pine therapy (10, 20, 40/5, 10 mg) was significantly more
effective than amlodipine monotherapy in mild to moder-
ate hypertensive patients, of which 79.3% had stage 2
hypertension [21]
Although reductions in blood pressure may be
affected by ethnic/racial difference and baseline blood
pressure levels, the data from this study and the results
from previous clinical trials demonstrate the efficacy of
ARB and amlodipine combination therapy in treating
stage 2 hypertension and support the recommendation
that in patients who do not achieve recommended
blood pressure reductions with a low dose of an antihy-
pertensive agent, a combination therapy may be more
effective than increasing the dose of a single agent.
H o w e v e r ,am o r ec o s t - e f f e c t i v eo p t i o nm a yb et ou s e
combination therapy first-line to achieve blood pressure
goals quickly. The ability to generalize these results to
the population as a whole, and especially to older
patients, is limited by the small number of patients
included and by the lack of ethnic diversity. Larger stu-
dies are warranted in more diverse populations. The
results of the secondary and exploratory endpoints
should be interpreted with caution since no adjustments
were made for multiplicity.
Conclusions
In conclusion, the results of this trial support the use of
early initiation of amlodipine/losartan combination fol-
lowed by subsequent dose escalation in patients who
have not achieved recommended blood pressure levels.
Amlodipine/losartan was generally well-tolerated and
provides a superior first-line therapeutic option for
patients with stage 2 hypertension.
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